0000899243-20-005517.txt : 20200221
0000899243-20-005517.hdr.sgml : 20200221
20200221184257
ACCESSION NUMBER: 0000899243-20-005517
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200219
FILED AS OF DATE: 20200221
DATE AS OF CHANGE: 20200221
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Katkin Keith
CENTRAL INDEX KEY: 0001314596
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38667
FILM NUMBER: 20641567
MAIL ADDRESS:
STREET 1: C/O UROVANT SCIENCES, INC.
STREET 2: 5281 CALIFORNIA AVENUE, SUITE 100
CITY: IRVINE
STATE: CA
ZIP: 92617
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Urovant Sciences Ltd.
CENTRAL INDEX KEY: 0001740547
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: D0
FISCAL YEAR END: 0331
BUSINESS ADDRESS:
STREET 1: 5281 CALIFORNIA AVENUE
STREET 2: SUITE 100
CITY: IRVINE
STATE: CA
ZIP: 92617
BUSINESS PHONE: 949-226-6029
MAIL ADDRESS:
STREET 1: 5281 CALIFORNIA AVENUE
STREET 2: SUITE 100
CITY: IRVINE
STATE: CA
ZIP: 92617
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-02-19
0
0001740547
Urovant Sciences Ltd.
UROV
0001314596
Katkin Keith
C/O UROVANT SCIENCES, INC.
5281 CALIFORNIA AVENUE, SUITE 100
IRVINE
CA
92617
1
1
0
0
PEO;CEO/Urovant Sciences, Inc.
Common Shares
2020-02-19
4
M
0
180000
3.86
A
379680
D
Common Shares
2020-02-19
4
F
0
104788
13.08
D
274892
D
Common Shares
2020-02-19
4
J
0
75212
13.08
D
199680
D
Stock Option (Right to Buy)
3.86
2020-02-19
4
M
0
180000
0.00
A
2027-09-21
Common Shares
180000
701254
D
Represents 53,119 shares surrendered to the Issuer in satisfaction of payment of exercise price and 51,669 shares surrendered to the Issuer in satisfaction of the payment of required withholding taxes in connection with the exercise of stock options.
Represents the sale of 75,212 shares of common stock to Sumitovant Biopharma Ltd., a subsidiary of Dainippon Sumitomo Pharma, in a privately-negotiated transaction.
All of the shares underlying this option are vested and exercisable as of the date hereof.
Following the reported transactions, the Reporting Person beneficially owns options to purchase an aggregate of 1,416,166 common shares (inclusive of the options reported in Table II, Column 9 above).
/s/ Bryan Smith, Attorney-in-Fact
2020-02-21